Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07199335 · ClinicalTrials.gov registry record · Phase 4
Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs
A Phase 4 study of HIV and Substance Use Disorder (SUD), sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT07199335 is a Phase 4 study of HIV and Substance Use Disorder (SUD) that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07199335, a Phase 4 study of HIV and Substance Use Disorder (SUD), is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to determine the feasibility and impact of delivering long-acting injectable cabotegravir HIV pre-exposure prophylaxis and suite of support services to adults who inject non-prescription drugs who are risk for HIV through known sexual risk.
Conditions Studied
Interventions
- DRUG APRETUDE (cabotegravir)
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Fenway Health - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-02-24 |
| Est. Completion | 2028-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07199335
The ClinicalTrials.gov registry entry for NCT07199335 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (77% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which APRETUDE (cabotegravir) is the first listed.
NCT07199335 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07199335 about?
NCT07199335 is a clinical study titled "Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs". The goal of this study is to determine the feasibility and impact of delivering long-acting injectable cabotegravir HIV pre-exposure prophylaxis and suite of support services to adults who inject non-prescription drugs who are risk for HIV through known sexual risk.
What is the current status of trial NCT07199335?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2026-02-24. Estimated completion is 2028-12.
What conditions does trial NCT07199335 study?
This clinical trial studies the following conditions: HIV, Substance Use Disorder (SUD), Injection Drug Use.
What interventions are being tested in trial NCT07199335?
The interventions under investigation include: APRETUDE (cabotegravir) (DRUG).
Who is sponsoring clinical trial NCT07199335?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07199335 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
RECRUITING · Phase 4
-
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
RECRUITING · Phase 4
-
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
RECRUITING · Phase 4
-
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
RECRUITING · Phase 4
-
Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
ACTIVE NOT RECRUITING · Phase 4
-
Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.